
On Friday, French pharmaceutical firm Sanofi reduced its insulin price for uninsured patients in the US significantly. This comes as the Affordable Insulin Now Act has passed the House of Representatives, and a bi-partisan bill to cap costs is being introduced to the Senate.
Through Sanofi’s Insulins Valyou initiative, US diabetes patients without insurance but with a valid prescription will be able to get 30 days’ worth of one of the company’s insulin products for USD 35 – the exact price cap proposed by both bills.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app